bms-986507
Small moleculeexperimental
Clinical trial activity
4 trials · 2 clinical orgs · 0 marketing orgs
Phase 1
1
Phase 2
1
Phase 3
3
Phase 4
0
Earliest trial started Nov 25, 2024 (NCT06618287)
Timeline
Indications
Mechanism of action
- UnclearUnclear
Unclear unclear
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07100080 | Phase 2/Phase 3 (Phase 3) | Nov 5, 2025 | Bristol-Myers Squibb |
| NCT07106762 | Phase 2/Phase 3 (Phase 3) | Sep 30, 2025 | Bristol-Myers Squibb |
| NCT06926868 | Phase 2/Phase 3 (Phase 3) | Sep 11, 2025 | Bristol-Myers Squibb, SystImmune Inc. |
| NCT06618287 | Phase 1/Phase 2 (Phase 2) | Nov 25, 2024 | Bristol-Myers Squibb |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bristol-Myers Squibb | For profit | 4 | 4 | 2 | 2024 |
| SystImmune Inc. | For profit | 1 | 0 | 1 | 2025 |
2 organizations
Page 1 / 1